Voices
FDA Approval

Rahul Gosain: TROPION-Lung01 and Lung05 Study that Resulted in DatoDXd FDA Approval

Rahul Gosain, Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, shared a post on LinkedIn:

“One page takeaway/summary from our with Jacob Sands and TROPION-Lung01 and Lung05 study that resulted in DatoDXd FDA approval on June 23, 2025 for previously treated mEGFR NSCLC!”

graphical user interface, text, application

More posts featuring Rahul Gosain on OncoDaily.

cancer DatoDXd FDA Jacob Sands Lung05 NSCLC OncoDaily Oncology Rahul Gosain TROPION-Lung01